MolecularMD Licenses NYU, MSKCC Patents to Develop PGx Test for BRAF Mutation | GenomeWeb

Pharmacogenomic test developer Molecular MD has been granted a license by New York University and Memorial Sloan-Kettering Cancer Center to intellectual property pertaining to detecting the BRAF V600E mutation, the company said this week.

MolecularMD, a Portland-based spinout of Oregon Health and Science University, said it will use the IP to develop a sensitive, clinically validated test to help identify cancer patients likely to benefit from treatment with BRAF inhibitors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.